河南省人民医院
Henan Provincial People's Hospital
在本站收录的 61 种疾病中,这家医院列在其中 37 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。
这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。
这家医院的官网还没有核对。
河南省人民医院的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 61 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 鼻咽癌Nasopharyngeal carcinoma3 篇牵头论文
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma20 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma30 篇牵头论文
- 胃癌Stomach cancer25 篇牵头论文
- 肺癌Lung cancer66 篇牵头论文
- 胰腺癌Pancreatic cancer13 篇牵头论文
- 乳腺癌Breast cancer39 篇牵头论文
- 胶质瘤Glioma56 篇牵头论文牵头 6 项开放试验
- 视网膜母细胞瘤Retinoblastoma2 篇牵头论文
- 脊索瘤Chordoma0 篇牵头论文
- 骨肉瘤Osteosarcoma7 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour0 篇牵头论文
- 神经母细胞瘤Neuroblastoma3 篇牵头论文
- 尤文肉瘤Ewing sarcoma0 篇牵头论文
- 多发性骨髓瘤Multiple myeloma5 篇牵头论文
- 淋巴瘤Lymphoma13 篇牵头论文
- 血友病 AHaemophilia A2 篇牵头论文
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
- 范可尼贫血Fanconi anaemia1 篇牵头论文
- 视神经脊髓炎谱系疾病Neuromyelitis optica spectrum disorder2 篇牵头论文
- 重症肌无力Myasthenia gravis2 篇牵头论文
- 烟雾病Moyamoya disease5 篇牵头论文
- 冠心病Coronary heart disease26 篇牵头论文
- 先天性心脏病Congenital heart disease14 篇牵头论文
- 脊柱侧弯Scoliosis0 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis2 篇牵头论文
- 大动脉炎Takayasu arteritis0 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis5 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis1 篇牵头论文
- 杜氏肌营养不良Duchenne muscular dystrophy1 篇牵头论文
- IgA 肾病IgA nephropathy1 篇牵头论文
- 成骨不全症Osteogenesis imperfecta0 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis0 篇牵头论文
- 原发性硬化性胆管炎Primary sclerosing cholangitis0 篇牵头论文
- 遗传性大疱性表皮松解症Inherited epidermolysis bullosa2 篇牵头论文
- 遗传性血管性水肿Hereditary angioedema0 篇牵头论文
- Leber 遗传性视神经病变Leber hereditary optic neuropathy3 篇牵头论文
未列出的收录疾病:肝母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、非典型溶血性尿毒症综合征、IgG4相关性疾病、肝豆状核变性、胆道闭锁、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、白塞病、Alport 综合征、戈谢病、尼曼-匹克病 C 型、先天性膈疝、先天性巨结肠、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
鼻咽癌
Nasopharyngeal carcinoma2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 4 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的鼻咽癌开放试验。
这些数字背后的记录
牵头的论文3
- miR-34c-3p Inhibits Nasopharyngeal Carcinoma Development via Inhibiting M2 Polarization of Macrophages.
- Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
- Hsa_circ_0000345 inhibits cell proliferation, migration and invasion of nasopharyngeal carcinoma cells via miR-513a-3p/PTEN axis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
PubMed 以外找到的论文(未计入)10
- Additional file 1 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 2 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 3 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 4 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 5 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 6 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 7 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 8 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Additional file 9 of Circular RNA circPVT1 promotes nasopharyngeal carcinoma metastasis via the β-TrCP/c-Myc/SRSF1 positive feedback loop
- Long intergenic non-protein coding RNA 02570 promotes nasopharyngeal carcinoma progression by adsorbing microRNA miR-4649-3p thereby upregulating both sterol regulatory element binding protein 1, and fatty acid synthase
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 20 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 6 家医院列在食管鳞状细胞癌下全国有 192 家医院列在食管鳞状细胞癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
- 分期
- 未注明
- 开始
- 2022-07
- 发布
- 登记号
- NCT05443841
年龄未注明(登记的条件)
牵头:复旦大学附属肿瘤医院;另有 8 家列出的医院为研究中心上海、南通、合肥、天津、泰州、石家庄、西安、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文20
- Biocompatible hydrogel co-delivering salvigenin and iridium (III) complex overcomes cancer stemness and cisplatin resistance in esophageal squamous cell carcinoma.
- Multi-omics analysis unveils a four-gene prognostic signature in esophageal squamous carcinoma and the therapeutic potential of PKP1.
- Perioperative the BTLA inhibitor (tifcemalimab) combined with toripalimab and chemotherapy for resectable locally advanced thoracic esophageal squamous cell carcinoma trial (BT-NICE trial): a prospective, single-arm, exploratory study.
- METTL3-Mediated m6A Methylation Stabilizes IFI27 to Drive Esophageal Squamous Cell Carcinoma Progression Through an IGF2BP2-Dependent Mechanism.
- Screening, Validation, and Machine Learning-Based Evaluation of Serum Protein Biomarkers for Esophageal Squamous Cell Carcinoma Based on Single-Cell Subtype-Specific Genes.
- Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula.
- Arntl-induced upregulation of DUSP1 inhibits tumor progression in esophageal squamous cell carcinoma by inactivating ERK signaling.
- DNMT1-driven methylation of RORA facilitates esophageal squamous cell carcinoma progression under hypoxia through SLC2A3.
- EVA1B facilitates esophageal squamous carcinoma progression and recruitment of immunosuppressive myeloid-derived suppressor cells in the tumor microenvironment.
- The anti-tumor activity of tangeretin in esophageal squamous cell carcinoma by inhibiting GLI2-mediated transcription of GPNMB.
- LincRNA-P21 knockdown facilitates esophageal squamous cell carcinoma cell progression by upregulating cadherin 5 via YTH domain containing 1.
- Exosomal circ_0026611 contributes to lymphangiogenesis by reducing PROX1 acetylation and ubiquitination in human lymphatic endothelial cells (HLECs).
- Hsa_circ_0046534 accelerates esophageal squamous cell carcinoma proliferation and metastasis via regulating MMP2 expression by sponging miR-339-5p.
- The efficacy and safety of sintilimab combined with chemotherapy as the first-line treatment for metastatic esophageal squamous cell carcinoma.
- DNA methyltransferase 3 beta regulates promoter methylation of microRNA-149 to augment esophageal squamous cell carcinoma development through the ring finger protein 2/Wnt/β-catenin axis.
- HA-ADT suppresses esophageal squamous cell carcinoma progression via apoptosis promotion and autophagy inhibition.
- Identification of a novel circ_0001946/miR-1290/SOX6 ceRNA network in esophageal squamous cell cancer.
- Fusobacterium nucleatum predicts a high risk of metastasis for esophageal squamous cell carcinoma.
- RELT promotes the growth of esophageal squamous cell carcinoma by activating the NF-κB pathway.
- TMEM161B-AS1 suppresses proliferation, invasion and glycolysis by targeting miR-23a-3p/HIF1AN signal axis in oesophageal squamous cell carcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)
- TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.
- A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
PubMed 以外找到的论文(未计入)9
- 2119P Perioperative study of BTLA combined with PD-1 and chemotherapy as bispecific immunosuppressants for resectable thoracic esophageal squamous cell carcinoma (BT-NICE trial): A prospective, single group, phase II study
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Encouraging efficacy of sintilimab combined with nanoparticle albumin-bound paclitaxel and platinum as the first-line treatment for metastatic esophageal squamous cell carcinoma: A retrospective study.
- Preliminary study on the role and mechanism of KIRREL3 in the development of esophageal squamous cell carcinoma (ESCC)
- LRP16 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma by Regulating Hippo Signaling Pathway
- LncRNA HCP5 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/mTOR signaling
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 30 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 3 家医院列在肝细胞癌下全国有 194 家医院列在肝细胞癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- 分期
- 未注明
- 开始
- 2025-09
- 发布
- 登记号
- NCT07170345
年龄 18 岁 至 18 岁(登记的条件)
牵头方不是列出的医院;另有 13 家列出的医院为研究中心上海、北京、南宁、广州、成都、沈阳、温州、珠海、福州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文30
- WTAP contributes to the malignancy and stemness of hepatocellular carcinoma through upregulating N6-methyladenosine modification of ITGB4.
- Value of Abbreviated Magnetic Resonance Sequence in Hepatocellular Carcinoma Screening: A Systematic Review and Meta-analysis.
- HLA-DR⁺ Tumor Cells Show an Association with a Distinct Immune Microenvironment and CD8⁺ T-Cell Exhaustion in HBV-Associated Hepatocellular Carcinoma.
- Imaging-Based Prediction of Ki-67 Expression in Hepatocellular Carcinoma: A Retrospective Study.
- Multi-omics spatial characteristics of CD8+TRM cells in hepatocellular carcinoma and immunotherapy response prediction.
- The safety and effectiveness of sintilimab versus camrelizumab, both plus targeted drugs, in advanced hepatocellular carcinoma.
- Integrated bioinformatics and in vitro validation reveal TUBB as a core gene and therapeutic target in NAFLD-related hepatocellular carcinoma.
- Increased expression of DNAJC7 promotes the progression of hepatocellular carcinoma by influencing the cell cycle and immune microenvironment.
- FAIM modulates HCC progression via enhancing HMGA1 interaction with CDK7 and promoting its phosphorylation level.
- Transcriptional regulation of tumor suppressor gene RASSF1A by HBx.
- OTUD7B is a new deubiquitinase targeting p53.
- Proteo-genomic characterization of cirrhosis-associated liver cancers reveals potential subtypes and therapeutic targets.
- Myocardial and Cerebral Infarction after Transarterial Bland Microsphere Embolization for Hepatocellular Carcinoma: A Case Report.
- TDF and TAF inhibit liver cancer cell migration, invasion via p7TP3.
- LncRNA RP11-620J15.3 promotes HCC cell proliferation and metastasis by targeting miR-326/GPI to enhance glycolysis.
- Noninvasive Prediction of Ki-67 Expression in Hepatocellular Carcinoma Using Machine Learning-Based Ultrasomics: A Multicenter Study.
- Long non-coding RNA HAGLROS facilitates tumorigenesis and progression in hepatocellular carcinoma by sponging miR-26b-5p to up-regulate karyopherin α2 (KPNA2) and inactivate p53 signaling.
- LINC01419 Promotes the Proliferation of Hepatoma Cells by Recruiting XRCC5 and Regulating Its Phosphorylation to Repair DNA Damage.
- Hydroxyacid Oxidase 2 (HAO2) Inhibits the Tumorigenicity of Hepatocellular Carcinoma and Is Negatively Regulated by miR-615-5p.
- LncRNA MAPKAPK5_AS1 facilitates cell proliferation in hepatitis B virus -related hepatocellular carcinoma.
- The long non-coding RNA LIMT inhibits metastasis of hepatocellular carcinoma and is suppressed by EGF signaling.
- Sarcopenia as an Independent Risk Factor for Specific Cancers: A Propensity Score-Matched Asian Population-Based Cohort Study.
- Deciphering the molecular mechanism of tetrandrine in inhibiting hepatocellular carcinoma and increasing sorafenib sensitivity by combining network pharmacology and experimental evaluation.
- Evaluation of Glypican-3 Expression in Hepatocellular Carcinoma by Using IDEAL IQ Magnetic Resonance Imaging.
- miR-199a-5p inhibits the proliferation of hepatocellular carcinoma cells by regulating CDC25A to induce cell cycle arrest.
- Immune-associated molecular occurrence and prognosis predictor of hepatocellular carcinoma: an integrated analysis of GEO datasets.
- Development of an AI system for accurately diagnose hepatocellular carcinoma from computed tomography imaging data.
- ZSCAN16-AS1 expedites hepatocellular carcinoma progression via modulating the miR-181c-5p/SPAG9 axis to activate the JNK pathway.
- Hybrid network with difference degree and attention mechanism combined with radiomics (H-DARnet) for MVI prediction in HCC.
- CircRNA GFRA1 promotes hepatocellular carcinoma progression by modulating the miR-498/NAP1L3 axis.
中文论文(未计入)2
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
- A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)
- Nurse-led Decision Counseling on Hepatocellular Carcinoma Screening
- Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 25 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 4 家医院列在胃癌下全国有 211 家医院列在胃癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胃癌开放试验。
这些数字背后的记录
牵头的论文25
- Spatial transcriptomic characteristics of gastric cancer in young and the expression and role of TMEM176B in gastric cancer cells.
- Global Prevalence of Helicobacter pylori Infection-Associated Gastric Preneoplastic Lesions in Pediatric Patients: A Systematic Review and Meta-Analysis.
- An interpretable hybrid deep learning framework for gastric cancer diagnosis using histopathological imaging.
- The three-stage and seven-step method for laparoscopic radical gastrectomy: A new surgical procedure for gastric cancer.
- Pathological complete remission (PCR) in a patient with unresectable gastric cancer undergoing preoperative conversion therapy.
- Family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are highly cost-effective in preventing multiple upper gastrointestinal diseases in Chinese population at national level.
- Benzimidazole-based structure optimization to discover novel anti-gastric cancer agents targeting ROS/MAPK pathway.
- Sensitivity and specificity of folate receptor α-positive circulating tumour cells in gastric cancer.
- Comprehensive analysis of risk factors associated with submucosal invasion in patients with early-stage gastric cancer.
- Relationship between the number of dissected lymph node and the pathological staging in esophagogastric junction adenocarcinoma.
- Identification of a seven-cell cycle signature predicting overall survival for gastric cancer.
- Feasibility and Tolerance of Apatinib plus PD-1 Inhibitors for Previously Treated Advanced Gastric Cancer: A Real-World Exploratory Study.
- Non-invasive measurement of tumor immune microenvironment and prediction of survival and chemotherapeutic benefits from 18F fluorodeoxyglucose PET/CT images in gastric cancer.
- Both family-based Helicobacter pylori infection control and management strategy and screen-and-treat strategy are cost-effective for gastric cancer prevention.
- "Two-Side Approach, Four-Step Dissociation" Surgical Technique for Splenic Hilar Lymphadenectomy During Laparoscopic Total Gastrectomy for Advanced Gastric Cancer.
- Plasma Exosomal hsa_circ_0015286 as a Potential Diagnostic and Prognostic Biomarker for Gastric Cancer.
- Family-based Helicobacter pylori infection status and transmission pattern in central China, and its clinical implications for related disease prevention.
- Gastric mucosal precancerous lesions in Helicobacter pylori-infected pediatric patients in central China: A single-center, retrospective investigation.
- Knockdown of hsa_circ_0091994 constrains gastric cancer progression by suppressing the miR-324-5p/HMGA1 axis.
- A novel circular RNA circ_HN1/miR-628-5p/Ecto-5'-nucleotidase competing endogenous RNA network regulates gastric cancer development.
- Tissue-based metabolomics reveals metabolic signatures and major metabolic pathways of gastric cancer with help of transcriptomic data from TCGA.
- CDC42EP3 is a key promoter involved in the development and progression of gastric cancer.
- m6 A transferase KIAA1429-stabilized LINC00958 accelerates gastric cancer aerobic glycolysis through targeting GLUT1.
- Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells.
- STROBE-clinical characteristics and prognosis factors of gastric cancer in young patients aged ≤30 years.
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- HFNO Reduces Hypoxia During Sedated Gastroscopy or Colonoscopy in High Risk Patients
- Nasal Mask Kit in Gastrointestinal Endoscopy
- Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly Patients
- HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
- Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
- A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
癌症
肺癌
Lung cancer2021–2025 年中国大陆作者发表的 23,356 篇肺癌 PubMed 英文论文中,这家医院牵头了 66 篇,占 0.3%。
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 3 家医院列在肺癌下全国有 251 家医院列在肺癌下
这家医院参与的开放试验 9
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- 分期
- III期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07416474
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 66 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、太原、安阳、广州、徐州、成都、新乡、昆明、杭州、桂林、武汉、江门、沈阳、洛阳、济南、深圳、温州、烟台、珠海、石家庄、福州、苏州、襄阳、郑州、重庆、银川、长春、长沙、青岛
- 正在招募A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
- 分期
- II期
- 开始
- 2026-02
- 发布
- 登记号
- NCT07444437
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 3 家列出的医院为研究中心广州、郑州
- 正在招募Pragmatic AI-Assisted Lung Cancer Translational Study
- 分期
- 不分期
- 开始
- 2026-08
- 发布
- 登记号
- NCT07941128
年龄 18 岁 至 未注明(登记的条件)
牵头:浙江大学医学院附属邵逸夫医院;另有 1 家列出的医院为研究中心杭州、郑州
- 正在招募A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- 分期
- III期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07217301
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、北京、南京、南昌、合肥、哈尔滨、天津、广州、徐州、成都、新乡、昆明、杭州、沈阳、泸州、济南、温州、石家庄、福州、西安、郑州、重庆、长沙
- 正在招募D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- 分期
- III期
- 开始
- 2024-03
- 发布
- 登记号
- NCT06300177
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 63 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南宁、南昌、南通、厦门、合肥、哈尔滨、天津、太原、安阳、常州、广州、徐州、成都、新乡、无锡、昆明、杭州、桂林、武汉、沈阳、洛阳、济南、海口、温州、湛江、潍坊、石家庄、福州、西安、遵义、郑州、重庆、长春、长沙
- 正在招募Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
- 分期
- 不分期
- 开始
- 2024-09
- 发布
- 登记号
- NCT06572540
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、广州、成都、杭州、郑州
- 正在招募A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
- 分期
- I/II期
- 开始
- 2022-10
- 发布
- 登记号
- NCT07231068
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 5 家列出的医院为研究中心北京、广州、郑州
- 正在招募Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- 分期
- I/II期
- 开始
- 2021-09
- 发布
- 登记号
- NCT04930432
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 56 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、南通、厦门、台州、合肥、哈尔滨、大连、天津、太原、广州、徐州、成都、昆明、杭州、武汉、汕头、沈阳、济南、深圳、温州、潍坊、烟台、石家庄、福州、苏州、蚌埠、西安、郑州、重庆、长春、长沙、青岛
- 即将招募Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
- 分期
- 不分期
- 开始
- 2025-09
- 发布
- 登记号
- NCT07135297
年龄 18 岁 至 未注明(登记的条件)
牵头:上海市胸科医院;另有 4 家列出的医院为研究中心上海、北京、南京、宁波、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文66
- FBXL6 drives tumorigenesis in lung adenocarcinoma through ubiquitination and proteasomal degradation of CDKN1C.
- Targeting NAD + biosynthesis suppresses TGF-β1/Smads/RAB26 axis and potentiates cisplatin cytotoxicity in non-small cell lung cancer brain metastasis.
- Prognostic performance of the nutritional risk screening 2002 and the global leadership initiative on malnutrition in patients with lung cancer treated with immune checkpoint inhibitors.
- Metabolic and multi-model intravoxel incoherent motion parameters based 18F-FDG PET/MRI for predicting subtypes of inoperable non-small cell lung cancer.
- Identification of a Risk Signature and Immune Cell Infiltration Based on Extracellular Matrix-Related lncRNAs in Lung Adenocarcinoma.
- Effect of Nebulized Dexmedetomidine on Postoperative Nausea and Vomiting in Female Patients Undergoing Radical Thoracoscopic Lung Cancer Resection: A Single-Center Randomized Controlled Trial.
- Influence of diabetes mellitus on metabolic networks in lung cancer patients: an analysis using dynamic total-body PET/CT imaging.
- Targeting BUB1B-driven cancer stemness in lung adenocarcinoma: a novel therapeutic strategy via PI3K/AKT pathway modulation.
- Association between high-density lipoprotein cholesterol and 7-autoantibodies: a study on physical examination data from 2018 to 2023.
- Targeted and personalized immunotherapy in lung adenocarcinoma: single-cell RNA sequencing of MAFF+ tumor cells and the therapeutic potential of FOS.
- Tri-Compartmental Restriction Spectrum Imaging Based on 18F-FDG PET/MR for Identification of Primary Benign and Malignant Lung Lesions.
- Assessment of Lung Nodule Detection and Lung CT Screening Reporting and Data System Classification Using Zero Echo Time Pulmonary MRI.
- Multiparametric 18F-FDG PET/MRI based on restrictive spectrum imaging and amide proton transfer-weighted imaging facilitates the assessment of lymph node metastases in non-small cell lung cancer.
- Exploring the mechanism of the potential effects of Liujunzi Tang combined with Suanzaoren Tang in the treatment of lung cancer with insomnia based on network pharmacology and molecular docking technology.
- CXCR1 and CXCR2 Antagonism with G31P Attenuates Chemotherapy-Induced Lung Inflammation and Augments the Gefitinib Therapeutic Response in Lung Cancer.
- Feedforward control with personalized nursing measures on respiratory function and psychological status in patients with advanced lung cancer.
- Shape sensing robotic assisted bronchoscopy versus virtual bronchoscopic navigation in the diagnosis of peripheral pulmonary nodules.
- The prognostic value of sarcopenia and sarcopenic obesity in patients with lung cancer receiving immunotherapy: a propensity score matching study.
- Effects of penehyclidine hydrochloride on postoperative nausea and vomiting in patients who underwent radical thoracoscopic lung cancer surgery: study protocol for a single-center, prospective, randomized controlled clinical trial.
- Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy.
- Predictive value of metabolic parameters and apparent diffusion coefficient derived from 18F-FDG PET/MR in patients with non-small cell lung cancer.
- Effect of age on postoperative 24-hour moderate-to-severe pain after radical resection of lung cancer-specific pain in the post-anaesthesia care unit: a single-centre retrospective cohort study.
- The deubiquitinating protein OTUD6B promotes lung adenocarcinoma progression by stabilizing RIPK1.
- The Correlation Between the Natural Course, Pathologic Properties With Ki-67 Expression in Lung Adenocarcinoma Presenting as Ground-Glass Nodules.
- Reporting quality evaluation of clinical practice guidelines for pulmonary nodules with the RIGHT checklist.
- An [18F]FDG PET/3D-ultrashort echo time MRI-based radiomics model established by machine learning facilitates preoperative assessment of lymph node status in non-small cell lung cancer.
- CD146 Promotes EMT-Mediated Migration and Invasion of NSCLC via PI3K/Akt Signaling Pathway.
- Effect of multidisciplinary team-style continuity of care and nutritional nursing on lung cancer: randomized study.
- Comprehensive analysis of single-cell transcriptomics and genetic factors reveals the mechanisms and preventive strategies for the progression from pulmonary fibrosis to lung cancer.
- Effect of preoperative natural killer cell on postoperative pulmonary complications in patients of lung cancer - A single-center retrospective cohort study.
- SFXN1-mediated immune cell infiltration and tumorigenesis in lung adenocarcinoma: A potential therapeutic target.
- Multiple primary lung cancer: Updates and perspectives.
- Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.
- Amide Proton Transfer-Weighted Imaging and Multiple Models Intravoxel Incoherent Motion-Based 18F-FDG PET/MRI for Predicting Progression-Free Survival in Non-Small Cell Lung Cancer.
- Attention pyramid pooling network for artificial diagnosis on pulmonary nodules.
- Endobronchial Ultrasound-Based Support Vector Machine Model for Differentiating between Benign and Malignant Mediastinal and Hilar Lymph Nodes.
- Advances in the Treatment of Pulmonary Nodules.
- Fear of progression among postoperative patients with newly diagnosed lung cancer: a cross-sectional survey in China.
- Building Awareness of Diagnosis Together: Ambiguity During Progression-Free Survival Experienced by Patients With Lung Cancer and Caregivers in China.
- Comparative immunological landscape between pre- and early-stage LUAD manifested as ground-glass nodules revealed by scRNA and scTCR integrated analysis.
- Bronchoscopic transparenchymal nodule access in the diagnosis and management of pulmonary nodules.
- Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy.
- Construction and validation of an efferocytosis-related prognostic signature in lung adenocarcinoma.
- Feasibility and Safety of Endosonography-Guided Transvascular Needle Aspiration in the Diagnosis of Thoracic and Abdominal Lesions: A Meta-Analysis.
- A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer.
- A diagnostic classification of lung nodules using multiple-scale residual network.
- Transcriptome analysis reveals the differential inflammatory effects between propofol and sevoflurane during lung cancer resection: a randomized pilot study.
- Extrinsic emotional regulation experienced by lung cancer patients and their family caregivers during progression-free survival.
- Identifying the individual metabolic abnormities from a systemic perspective using whole-body PET imaging.
- Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.
- Identification of Benign and Malignant Lung Nodules in CT Images Based on Ensemble Learning Method.
- Application of Simultaneous 18 F-FDG PET With Monoexponential, Biexponential, and Stretched Exponential Model-Based Diffusion-Weighted MR Imaging in Assessing the Proliferation Status of Lung Adenocarcinoma.
- Evaluation of Amide Proton Transfer-Weighted Imaging for Lung Cancer Subtype and Epidermal Growth Factor Receptor: A Comparative Study With Diffusion and Metabolic Parameters.
- Application of rapid rehabilitation surgical concept in perioperative nursing of patients undergoing single-port thoracoscopic lobectomy.
- Effects of serratus anterior plane block and thoracic paravertebral nerve block on analgesia, immune function and serum tumor markers in patients after thoracoscopic radical resection of lung cancer.
- Diagnostic value of LungPoint navigation combined with EBUS-GS & ROSE in peripheral pulmonary nodules.
- Lotus leaf flavonoids induce apoptosis of human lung cancer A549 cells through the ROS/p38 MAPK pathway.
- Angio-associated migratory cell protein (AAMP) interacts with cell division cycle 42 (CDC42) and enhances migration and invasion in human non-small cell lung cancer cells.
- LncRNA GAS6-AS2 promotes non-small-cell lung cancer cell proliferation via regulating miR-144-3p/ MAPK6 axis.
- Risk assessment of malignancy in solitary pulmonary nodules in lung computed tomography: a multivariable predictive model study.
- Clinical and functional significance of a novel ferroptosis-related prognosis signature in lung adenocarcinoma.
- Total-body dynamic PET/CT of micro-metastatic lymph node in a patient with lung cancer.
- Natural killer cell exhaustion in lung cancer.
- Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis.
- Circ_0089823 reinforces malignant behaviors of non-small cell lung cancer by acting as a sponge for microRNAs targeting SOX4.
- Propofol suppresses lung cancer tumorigenesis by modulating the circ-ERBB2/miR-7-5p/FOXM1 axis.
中文论文(未计入)8
- [Male non gestational choriocarcinoma with widespread systemic metastasis: report of two cases].
- [circDDX17 targets miR-223-3p / RIP3 to regulate the proliferation and apoptosis of non-small cell lung cancer cells].
- [Primary synovial sarcoma of lung: a clinicopathological analysis of 12 cases].
- [Clinicopathological features of lung adenocarcinoma with mesothelioma like growth pattern: report of three cases].
- [Clinical characteristics of anti-CV2 antibody-associated neurological diseases].
- [Clinical features and prognosis of patients with leptomeningeal metastases].
- [The influence of cachexia on the immunotherapy efficacy of Sintilimab for non-small cell lung cancer].
- [Triptolide increases the radiosensitivity of lung cancer cells by inhibiting DNA repair and inducing apoptosis].
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
- Study of Anlotinib Combined With Pemetrexed in Patients With Advanced Nonsquamous NSCLC
- Conmana Combined With Thalidomide to Treat NSCLC
- A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer
- RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
- Pragmatic AI-Assisted Lung Cancer Translational Study
- A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
- Novel Thin Bronchoscope Versus Ultrathin Bronchoscope for the Diagnosis of Peripheral Pulmonary Nodules
- Transthoracic vs Transbronchial Cryoablation for Early-stage Peripheral Lung Cancer
- D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation
- Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
- A Study of Efbemalenograstim Alfa Injection for Stage IIIB or IV NSCLC Recieving Moderate-risk Febrile Neutropenia (FN) Chemotherapy Regimen With Risk Factors
- IN10018 Combination Therapy in Treatment-naïve ES-SCLC
- Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
- HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy
- A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer
- A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China
- Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
- Early Cancer Detection Test - Lung Cancer China
- A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients
- Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
- A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC
- Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
- Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China
癌症
胰腺癌
Pancreatic cancer2021–2025 年中国大陆作者发表的 5,743 篇胰腺癌 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 3 家医院列在胰腺癌下全国有 192 家医院列在胰腺癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer Patients
- 分期
- 未注明
- 开始
- 2024-04
- 发布
- 登记号
- NCT06375473
年龄 18 岁 至 100 岁(登记的条件)
牵头:北京协和医院;另有 7 家列出的医院为研究中心上海、北京、南宁、合肥、宁波、武汉、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文13
- Astragaloside IV promotes the apoptosis of pancreatic cancer cells by activating endoplasmic reticulum stress through the PERK/ATF4/CHOP signaling pathway.
- Comprehensive bioinformatics analysis of the prognostic value and immune infiltration of CAPN2 in pancreatic adenocarcinoma.
- SPP1 + macrophages facilitate pancreatic cancer progression via ITGB6-mediated interactions: evidence from integrated multi-omics analysis and experimental validation.
- Multi-omics integration and machine learning uncover molecular basal-like subtype of pancreatic cancer and implicate A2ML1 in promoting tumor epithelial-mesenchymal transition.
- PLK1 inhibition enhances gemcitabine-induced apoptosis through PLK1-dependent ERK1/2-Bim and AKT1/Noxa signals in pancreatic cancer cells.
- Immortalization-upregulated protein promotes pancreatic cancer progression by regulating NPM1/FHL1-mediated cell-cycle-checkpoint protein activity.
- Identification of a potential prognostic model combining pyroptosis-related gene with immune microenvironment for pancreatic ductal adenocarcinoma.
- Integrin αvβ3 and EGFR dual-targeted [64Cu]Cu-NOTA-RGD-GE11 heterodimer for PET imaging in pancreatic cancer mouse model.
- A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer.
- The clinical significance of circulating tumor cells and T lymphocyte subtypes in pancreatic cancer patients.
- Identifying cancer cell-secreted proteins that activate cancer-associated fibroblasts as prognostic factors for patients with pancreatic cancer.
- Clinical features and prognostic factors of elderly patients with metastatic pancreatic cancer: a population-based study.
- Predictive significance of tumor budding in postoperative liver metastasis of pancreatic neuroendocrine tumors.
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
癌症
乳腺癌
Breast cancer2021–2025 年中国大陆作者发表的 16,974 篇乳腺癌 PubMed 英文论文中,这家医院牵头了 39 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 3 家医院列在乳腺癌下全国有 219 家医院列在乳腺癌下
这家医院参与的开放试验 4
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募SMP-656 for HER2-Positive Advanced Breast Cancer
- 分期
- II期
- 开始
- 2026-08
- 发布
- 登记号
- NCT07726342
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 15 家列出的医院为研究中心北京、南京、合肥、广州、成都、杭州、武汉、沈阳、济南、石家庄、西安、郑州、长沙
- 正在招募A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- 分期
- II/III期
- 开始
- 2025-06
- 发布
- 登记号
- NCT06891833
年龄 18 岁 至 75 岁;仅女性(登记的条件)
牵头方不是列出的医院;另有 26 家列出的医院为研究中心上海、南宁、南昌、合肥、哈尔滨、天津、太原、安阳、广州、成都、杭州、洛阳、济南、海口、深圳、石家庄、福州、蚌埠、西安、郑州、重庆、长沙
- 正在招募A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- 分期
- 未注明
- 开始
- 2024-01
- 发布
- 登记号
- NCT06210776
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 41 家列出的医院为研究中心上海、乌鲁木齐、佛山、北京、南京、南昌、南通、合肥、哈尔滨、唐山、天津、太原、广州、徐州、成都、新乡、昆明、杭州、汕头、沈阳、洛阳、深圳、潍坊、珠海、福州、西安、郑州、银川、青岛
- 正在招募Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- 分期
- IV期
- 开始
- 2021-06
- 发布
- 登记号
- NCT04790305
年龄 18 岁 至 70 岁(登记的条件)
牵头:复旦大学附属肿瘤医院;另有 26 家列出的医院为研究中心上海、北京、南京、合肥、宁波、广州、扬州、武汉、沈阳、济南、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文39
- ATM promotes bone metastatic propensity of breast cancer by inducing osteoclastogenesis via the NFκB-CCL2 pathway.
- Identification of risk factors and development of predictive models for chronic postsurgical pain after modified radical mastectomy.
- Predictive value of shear wave elastography and molecular subtypes for postoperative efficacy in patients with early breast cancer.
- The chain mediating effects of psychological resilience and family support on the association between taste alteration and cancer anorexia among Chinese breast cancer patients undergoing chemotherapy: a cross-sectional study.
- FATE1: A cancer testis antigen with oncogenic functions - Prognostic biomarker and JAK2/STAT1-driven autophagy regulator in breast cancer.
- FAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome.
- Spinal Metastasis Pain Surveillance: A Comprehensive Imaging-Based Tool Design for Evaluating Metastatic Burden and Guiding Therapeutic Strategies.
- Appraising histone H4 lysine 5 lactylation as a novel biomarker in breast cancer.
- 18F-Radiolabeling and Evaluation of an AMD3465 Derivative for PET Imaging of CXCR4 in a Mouse Breast Tumor Model.
- Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy.
- Development and Validation of a Nomogram for Predicting Breast Malignancy in Male Patients Based on Clinical and Ultrasound Features.
- Functional evaluation of dendritic cells and extracellular vesicles as immunotherapy for breast cancer.
- Preoperative Radiotherapy Does Not Change the Existing Treatment Paradigm in Stage III Breast Cancer.
- LINC-PINT suppresses breast cancer cell proliferation and migration via MEIS2/PPP3CC/NF-κB pathway by sponging miR-576-5p.
- Excessive glutathione intake contributes to chemotherapy resistance in breast cancer: a propensity score matching analysis.
- Brain metastasis in de novo stage IV breast cancer.
- Outcome and Cost-Effectiveness Analysis of Long-acting G-CSF as Primary Prophylaxis of Neutropenia Induced by Chemotherapy in Breast Cancer Patients, From a Retrospective Study.
- Oxygen-independent alkyl radical nanogenerator enhances breast cancer therapy.
- A pan-cancer analysis of potassium channel tetramerization domain containing 12 in human cancer.
- Clinical, Pathological Complete Response, and Prognosis Characteristics of HER2-Low Breast Cancer in the Neoadjuvant Chemotherapy Setting: A Retrospective Analysis.
- KDM3B-ETF1 fusion gene downregulates LMO2 via the WNT/β-catenin signaling pathway, promoting metastasis of invasive ductal carcinoma.
- Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1α-induced transcription of CKAP2.
- HER2-low expression does not affect the clinical outcomes of metastatic breast cancer treated with CDK4/6 inhibitor: A real-world study.
- LncRNA CASC15 regulates breast cancer cell stemness via the miR-654-5p/MEF2D axis.
- Adjuvant postmastectomy radiotherapy might be associated with better survival in women with heart failure receiving total mastectomy.
- Radiomics Signatures Based on Multiparametric MRI for the Preoperative Prediction of the HER2 Status of Patients with Breast Cancer.
- Polymorphisms in lncRNA MIR2052HG and susceptibility to breast cancer in Chinese population.
- Removal of palpable lymph nodes during sentinel lymph node biopsy in breast cancer: Our experience.
- Development and validation of nomograms for predicting axillary non-SLN metastases in breast cancer patients with 1-2 positive sentinel lymph node macro-metastases: a retrospective analysis of two independent cohorts.
- FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling.
- Identification of a prognostic chemoresistance-related gene signature associated with immune microenvironment in breast cancer.
- Paravertebral block in regional anesthesia with propofol sedation reduces locoregional recurrence in patients with breast cancer receiving breast conservative surgery compared with volatile inhalational without propofol in general anesthesi
- FGFR1 Overexpression Induces Cancer Cell Stemness and Enhanced Akt/Erk-ER Signaling to Promote Palbociclib Resistance in Luminal A Breast Cancer Cells.
- Preparation and evaluation of ultrasound-mediated dual-targeted theragnostic systems utilising phase-changeable polymeric nanodroplets on the integrin αν β3 overexpressed breast cancer.
- A comparative study of the value of amide proton transfer-weighted imaging and diffusion kurtosis imaging in the diagnosis and evaluation of breast cancer.
- Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity.
- Long non-coding RNA ROR recruits histone transmethylase MLL1 to up-regulate TIMP3 expression and promote breast cancer progression.
- SAP-cGAN: Adversarial learning for breast mass segmentation in digital mammogram based on superpixel average pooling.
- Pathologic response rates for breast cancer stages as a predictor of outcomes in patients receiving neoadjuvant chemotherapy followed by breast-conserving surgery.
它在 ClinicalTrials.gov 上的全部试验(任何状态)10
- SMP-656 for HER2-Positive Advanced Breast Cancer
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
- Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
- A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.
- FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
- A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
- A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer
- Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment
- Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
癌症
胶质瘤
Glioma2021–2025 年中国大陆作者发表的 7,081 篇胶质瘤 PubMed 英文论文中,这家医院牵头了 56 篇,占 0.8%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 6 家医院列在胶质瘤下全国有 187 家医院列在胶质瘤下
这家医院参与的开放试验 6
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
- 分期
- II期
- 开始
- 2022-12
- 发布
- 登记号
- NCT05512351
年龄 18 岁 至 未注明(登记的条件)
牵头:河南省人民医院郑州
- 即将招募Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
- 分期
- II期
- 开始
- 2023-10
- 发布
- 登记号
- NCT05540275
年龄 18 岁 至 未注明(登记的条件)
牵头:河南省人民医院郑州
- 即将招募Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
- 分期
- II期
- 开始
- 2022-12
- 发布
- 登记号
- NCT05502991
年龄 18 岁 至 未注明(登记的条件)
牵头:河南省人民医院郑州
- 即将招募Study on Gene Evolution in Glioma Under Stress Therapy
- 分期
- 未注明
- 开始
- 2022-12
- 发布
- 登记号
- NCT05512325
年龄 18 岁 至 75 岁(登记的条件)
牵头:河南省人民医院郑州
- 即将招募Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma
- 分期
- 未注明
- 开始
- 2022-12
- 发布
- 登记号
- NCT05532969
年龄 18 岁 至 75 岁(登记的条件)
牵头:河南省人民医院郑州
- 即将招募Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
- 分期
- 未注明
- 开始
- 2022-12
- 发布
- 登记号
- NCT05541042
年龄 18 岁 至 未注明(登记的条件)
牵头:河南省人民医院郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文56
- Integrated single-cell and spatial transcriptomics uncover the prognostic, epigenetic, and immunological roles of FANCC in low-grade glioma.
- FAM111B as a biomarker influences the prognosis and immune microenvironment of low-grade gliomas.
- PSMC3IP as a prognostic biomarker and immunomodulatory regulator in low-grade glioma: insights from multi-omics and methylation analysis.
- Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas.
- POLD3 knockdown effects on low-grade glioma: insights from bioinformatics and experimental validation.
- Causal Association Between Immune Cell Traits and Risk of Multiple Malignant and Nonmalignant CNS Diseases: A Mendelian Randomization and Single-Cell Transcriptomic Analysis.
- Dynamic Monitoring of Circulating Tumor DNA to Predict the Risk of Non In Situ Recurrence of Postoperative Glioma: A Prospective Cohort Study.
- Development of a web-based tool for estimating individualized survival curves in glioblastoma using clinical, mRNA, and tumor microenvironment features with fusion techniques.
- The oncogenic role of CCDC34 in lower-grade gliomas: prognostic significance and therapeutic potential.
- Sulforaphane-cysteine inhibits α-tubulin/PD-L1/PFKFB4 axis leading to apoptosis in human glioblastoma.
- HERC5/ISG15 Enhances Glioblastoma Stemness and Tumor Progression by mediating SERBP1protein stability.
- Dynamic Tumor in Situ Fluid Circulating Tumor DNA Postsurgery Effectively Predicts Recurrence and Clinical Benefits for Glioblastomas.
- Zinc finger protein 800 (ZNF800) promotes proliferation and migration of lower-grade glioma and is associated with immune infiltration.
- DSN1 may predict poor prognosis of lower-grade glioma patients and be a potential target for immunotherapy.
- Assessment of MGMT promoter methylation status in glioblastoma using deep learning features from multi-sequence MRI of intratumoral and peritumoral regions.
- Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.
- WD repeat domain 76 predicts poor prognosis in lower grade glioma and provides an original target for immunotherapy.
- TME-Activated MnO2/Pt Nanoplatform of Hydroxyl Radical and Oxygen Generation to Synergistically Promote Radiotherapy and MR Imaging of Glioblastoma.
- Dynamics of tumor in situ fluid circulating tumor DNA in recurrent glioblastomas forecasts treatment efficacy of immune checkpoint blockade coupled with low-dose bevacizumab.
- Synthesis of gadolinium-enhanced glioma images on multisequence magnetic resonance images using contrastive learning.
- LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
- Genomic alterations of oligodendrogliomas at distant recurrence.
- Prognostic Significance of mRNA Expression RBBP8 or Its Methylation in Gliomas.
- Fear stress promotes glioma progression through inhibition of ferroptosis by enhancing FSP1 stability.
- PSRC1 Regulated by DNA Methylation Is a Novel Target for LGG Immunotherapy.
- RFX2 promotes tumor cell stemness through epigenetic regulation of PAF1 in spinal ependymoma.
- Caspase-3 in glioma indicates an unfavorable prognosis by involving surrounding angiogenesis and tumor cell repopulation.
- Granulocyte-macrophage colony stimulating factor enhances efficacy of nimustine rendezvousing with temozolomide plus irradiation in patients with glioblastoma.
- ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
- IKBKE regulates angiogenesis by modulating VEGF expression and secretion in glioblastoma.
- Berberine inhibits glioma cell migration and invasion by suppressing TGF-β1/COL11A1 pathway.
- TGIF1 overexpression promotes glioma progression and worsens patient prognosis.
- High expression of HOXA4 in patients with glioma indicates unfavorable clinical outcomes.
- Silencing IKBKE inhibits the migration and invasion of glioblastoma by promoting Snail1 degradation.
- Real-time longitudinal analysis of human gliomas reveals in vivo genome evolution and therapeutic impact under standardized treatment.
- CLSPN is a potential biomarker associated with poor prognosis in low-grade gliomas based on a multi-database analysis.
- Aberrantly high DEPDC1B expression leads to poor prognosis in patients with lower-grade gliomas.
- Identification of PYGL as a key prognostic gene of glioma by integrated bioinformatics analysis.
- MiR-222-3p inhibits formation of medulloblastoma stem-like cells by targeting Notch2/c-myc signaling pathway.
- Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.
- ITGB3BP is a potential biomarker associated with poor prognosis of glioma.
- Identification of an Inflammatory Response-Related Gene Signature to Predict Survival and Immune Status in Glioma Patients.
- DRAXIN as a Novel Diagnostic Marker to Predict the Poor Prognosis of Glioma Patients.
- Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report.
- Post-traumatic brain injury glioma: Characteristics, report of 2 cases report and literature review.
- A lightweight 3D UNet model for glioma grading.
- Long noncoding RNA SNHG9 facilitates growth of glioma stem-like cells via miR-326/SOX9 axis.
- LINC02381 contributes to cell proliferation and hinders cell apoptosis in glioma by transcriptionally enhancing CBX5.
- Significantly high expression of NUP37 leads to poor prognosis of glioma patients by promoting the proliferation of glioma cells.
- Circ-UBAP2 functions as sponges of miR-1205 and miR-382 to promote glioma progression by modulating STC1 expression.
- Genome-wide CRISPR/Cas9 screening identifies CARHSP1 responsible for radiation resistance in glioblastoma.
- Integrating real-time in vivo tumour genomes for longitudinal analysis and management of glioma recurrence.
- MYC/NBS1-Mediated DNA Damage Response is Involved in the Inhibitory Effect of Hydroxysafflor Yellow A on Glioma Cells.
- Exosomal transfer of miR‑25‑3p promotes the proliferation and temozolomide resistance of glioblastoma cells by targeting FBXW7.
- Overexpression of GINS4 is associated with poor prognosis and survival in glioma patients.
- Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients.
它在 ClinicalTrials.gov 上的全部试验(任何状态)9
- Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma
- Study on Gene Evolution in Glioma Under Stress Therapy
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma
- Correlation Between Psychological Stress and Progression of Diffuse Astrocytoma Towards Secondary Glioma
- Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma
- Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers
- Personalized Trial in ctDNA-level-relapse Glioblastoma
- Correlation Between Psychological Stress and Disease Progression in Newly Diagnosed Glioblastoma Patients
- Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
癌症
视网膜母细胞瘤
Retinoblastoma2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 5 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。
这些数字背后的记录
牵头的论文2
癌症
脊索瘤
Chordoma2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 3 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 7 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 8 家医院列在骨肉瘤下全国有 570 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文7
- Integrating single-cell transcriptomics, molecular docking, and dynamics simulations to characterize protein kinase X-linked mechanisms in osteosarcoma.
- Multomic analysis reveals the potential of LAG3 as a prognostic and immune biomarker and its validation in osteosarcoma.
- Exploration in the Mechanism of Ginsenoside Rg5 for the Treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.
- DNMT1 determines osteosarcoma cell resistance to apoptosis by associatively modulating DNA and mRNA cytosine-5 methylation.
- Multiproperty Polyethylenimine-Caged Platinum Nanoclusters Promote Apoptosis of Osteosarcoma Cells via Regulating the BAX-Bcl-2/Caspase-3/PARP Axis.
- Circular RNA circVRK1 suppresses the proliferation, migration and invasion of osteosarcoma cells by regulating zinc finger protein ZNF652 expression via microRNA miR-337-3p.
- Circ-XPR1 promotes osteosarcoma proliferation through regulating the miR-214-5p/DDX5 axis.
早期论文(2016–2020 年)7
- Comprehensive Characterization of Prognostic Long Noncoding RNAs in Osteosarcoma.
- MicroRNA-765 targets MTUS1 to promote the progression of osteosarcoma via mediating ERK/EMT pathway.
- miR‑9 depletion suppresses the proliferation of osteosarcoma cells by targeting p16.
- G-protein-coupled estrogen receptor suppresses the migration of osteosarcoma cells via post-translational regulation of Snail.
- LncRNA SNHG15 contributes to proliferation, invasion and autophagy in osteosarcoma cells by sponging miR-141.
- MicroRNA-139 inhibits the proliferation and migration of osteosarcoma cells via targeting forkhead-box P2.
- Small Molecule Survivin Inhibitor YM155 Displays Potent Activity Against Human Osteosarcoma Cells.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年没有牵头胃肠道间质瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 5 家医院列在胃肠道间质瘤下全国有 240 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 6 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
这些数字背后的记录
牵头的论文3
- miRNA326-5p Targets DKC1 Gene to Regulate Apoptosis-Related Proteins and Intervene in the Development of Neuroblastoma.
- The N-Myc-responsive lncRNA MILIP promotes DNA double-strand break repair through non-homologous end joining.
- SOX17 inhibits proliferation and invasion of neuroblastoma through CXCL12/CXCR4 signaling axis.
早期论文(2016–2020 年)5
- SNHG16 Silencing Inhibits Neuroblastoma Progression by Downregulating HOXA7 via Sponging miR-128-3p.
- FGF represses metastasis of neuroblastoma regulated by MYCN and TGF-β1 induced LMO1 via control of let-7 expression.
- [PDCD4 enhances the inhibitory effect of As(2)O(3) on the growth and NF-κB signaling pathway in neuroblastoma cells].
- [Effects of miR-144 on proliferation, apoptosis and cisplatin resistance by targeting MYCN in pediatric neuroblastoma].
- PEST-containing nuclear protein mediates the proliferation, migration, and invasion of human neuroblastoma cells through MAPK and PI3K/AKT/mTOR signaling pathways.
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年没有牵头尤文肉瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 3 家医院列在尤文肉瘤下全国有 134 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 4 家医院列在多发性骨髓瘤下全国有 175 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- 分期
- I期
- 开始
- 2026-05
- 发布
- 登记号
- NCT07477587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 46 家列出的医院为研究中心上海、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、宁波、广州、徐州、成都、无锡、杭州、武汉、沈阳、济南、深圳、温州、潍坊、石家庄、福州、苏州、蚌埠、贵阳、郑州、重庆、长沙、青岛
- 即将招募Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- 分期
- III期
- 开始
- 2026-06
- 发布
- 登记号
- NCT07569757
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、太原、广州、徐州、成都、承德、昆明、杭州、株洲、沈阳、泸州、济南、湛江、石家庄、蚌埠、西安、贵阳、郑州、重庆、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Long-term follow-up of patients with relapsed/refractory multiple myeloma after BCMA CAR-T-cell therapy.
- Role of the bone marrow microenvironment in multiple myeloma: Impact of niches on drug resistance mechanisms.
- High Red Blood Cell Distribution Width to Platelet Ratio is an Independent Poor Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma.
- Pathogenesis, clinical characteristics and personalized managements of multiple myeloma with chromosome 1 abnormalities.
- Combined immune score predicts the prognosis of newly diagnosed multiple myeloma patients in the bortezomib-based therapy era.
中文论文(未计入)4
- [The Value of sFLC and Serum Calcium in the Diagnosis and Prognosis of Multiple Myeloma Patients].
- [Analysis of clinical and prognostic characteristics of newly diagnosed multiple myeloma with myelofibrosis patients].
- [The significance of bone marrow immature plasma cell burden in the prognosis of newly diagnosed multiple myeloma patients].
- [Clinical and biological characteristics and prognosis of patients with biclonal multiple myeloma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- A Study of NINLARO® in Chinese Adults With Multiple Myeloma
- Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)
血液疾病
淋巴瘤
Lymphoma2021–2025 年中国大陆作者发表的 3,830 篇淋巴瘤 PubMed 英文论文中,这家医院牵头了 13 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 4 家医院列在淋巴瘤下全国有 199 家医院列在淋巴瘤下
这家医院参与的开放试验 9
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
- 分期
- I/II期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07496229
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、南京、南宁、太原、成都、武汉、温州、福州、郑州、重庆
- 正在招募A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- 分期
- II期
- 开始
- 2025-08
- 发布
- 登记号
- NCT07082686
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 27 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、合肥、天津、广州、成都、杭州、武汉、济南、福州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- 分期
- II期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07189065
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 38 家列出的医院为研究中心上海、临沂、北京、南京、南宁、南昌、厦门、合肥、大连、天津、太原、广州、徐州、成都、杭州、武汉、沈阳、洛阳、石家庄、福州、苏州、郑州、重庆、长春、长沙
- 正在招募A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- 分期
- III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06363994
年龄 60 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南昌、合肥、天津、太原、宁波、常州、广州、成都、杭州、武汉、沈阳、洛阳、济南、石家庄、福州、蚌埠、西安、郑州、重庆、长春、长沙
- 正在招募ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- 分期
- II/III期
- 开始
- 2024-05
- 发布
- 登记号
- NCT06378138
年龄 18 岁 至 80 岁(登记的条件)
牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南京、南宁、南昌、厦门、合肥、大连、天津、太原、宜昌、广州、成都、杭州、武汉、沈阳、洛阳、济南、淮安、石家庄、福州、蚌埠、西安、遵义、郑州、重庆、长春、长沙
- 正在招募A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- 分期
- II期
- 开始
- 2024-11
- 发布
- 登记号
- NCT06566586
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、乌鲁木齐、兰州、南宁、南昌、呼和浩特、哈尔滨、天津、太原、广州、武汉、泸州、西安、郑州、长沙
- 正在招募Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- 分期
- III期
- 开始
- 2023-12
- 发布
- 登记号
- NCT06082102
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 18 家列出的医院为研究中心上海、北京、南昌、大连、广州、成都、杭州、武汉、沈阳、烟台、蚌埠、西安、郑州、长沙、青岛
- 即将招募A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- 分期
- III期
- 开始
- 2026-10
- 发布
- 登记号
- NCT07784101
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 24 家列出的医院为研究中心上海、北京、南京、合肥、天津、广州、成都、昆明、杭州、武汉、沈阳、济南、石家庄、福州、西安、郑州、重庆、长沙
- 即将招募Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- 分期
- III期
- 开始
- 2026-10
- 发布
- 登记号
- NCT07896590
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 40 家列出的医院为研究中心上海、兰州、北京、南京、南昌、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、洛阳、济南、海口、石家庄、福州、西安、郑州、重庆、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文13
- Identification of the IFN-γ/IL-4 ratio as a prognostic biomarker and development of an immune-related prognostic model in diffuse large B-cell lymphoma.
- New hopes and challenges in targeted therapy and immunotherapy for primary central nervous system lymphoma.
- Comparative global burden analysis of lymphoma subtypes: a statistical evaluation of severity across global regions.
- Ferroptosis-related gene analysis revealing novel biomarkers and therapeutic targets in diffuse large B-cell lymphoma.
- ITK overexpression enhances T cell cytotoxicity against DLBCL through the TCR-Ca2+-Calcineurin-NFAT-IFN-γ pathway.
- Clinical Potential of Copy Number Aberration as a Diagnostic and Prognostic Biomarker in Lymphoma.
- Prognostic Value of 18F-FDG PET/CT Radiomics in Extranodal Nasal-Type NK/T Cell Lymphoma.
- Comparison between Endobronchial Ultrasound-Guided Transbronchial Node Biopsy and Transbronchial Needle Aspiration: A Meta-Analysis.
- NRF1-regulated CircNSUN2 promotes lymphoma progression through activating Wnt signaling pathway via stabilizing HMGA1.
- Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
- G protein nucleolar 3 promotes Non-Hodgkin lymphoma progression by activating the Wnt/β-catenin signaling pathway.
- MYC rearrangement but not extra MYC copies is an independent prognostic factor in patients with mantle cell lymphoma.
- Self-efficacy, psychological distress, and marital quality in young and middle-aged couples facing lymphoma: The mediating effect of dyadic coping.
中文论文(未计入)6
- [Primary adrenal NK/T cell lymphoma: a clinicopathologic analysis of six cases].
- [Clinicopathological features of mature T/NK cell lymphoma with aberrant CD20 or CD79α expression].
- [Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma].
- [Extranodal nasal type natural killer/T-cell lymphoma of the digestive system: a clinicopathological study of thirteen cases].
- [The expression and prognostic value of PD-1, TIM-3, LAG-3 and BTLA in extranodal NK/T cell lymphoma].
- [Efficacy and safety of PD-1 inhibitor combined with chemotherapy in the primary treatment of phase Ⅲ/Ⅳ extranodal nasal-type natural killer/T cell lymphoma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)18
- Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
- Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
- A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
- A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
- A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)
- Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
- A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
血液疾病
血友病 A
Haemophilia A2021–2025 年中国大陆作者发表的 272 篇血友病 A PubMed 英文论文中,这家医院牵头了 2 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 5 家医院列在血友病 A下全国有 132 家医院列在血友病 A下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血友病 A开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)4
- Multislice spiral computed tomography imaging in evaluating hemophilic arthropathy.
- [Clinical study on factor Ⅷ inhibitor in children with hemophilia A].
- Using synovial volume measurement by MRI to evaluate the effect of 32P Radiation synovectomy on hemophilic arthropathy patients.
- [Therapeutic response of radiosynovectomy with p-32 colloid in 326 patients with hemophilic arthropathy].
它在 ClinicalTrials.gov 上的全部试验(任何状态)7
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
- Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
- Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 2 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
血液疾病
范可尼贫血
Fanconi anaemia2021–2025 年中国大陆作者发表的 68 篇范可尼贫血 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 2 家医院列在范可尼贫血下全国有 40 家医院列在范可尼贫血下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的范可尼贫血开放试验。
其他疾病
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder2021–2025 年中国大陆作者发表的 485 篇视神经脊髓炎谱系疾病 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 2 家医院列在视神经脊髓炎谱系疾病下全国有 67 家医院列在视神经脊髓炎谱系疾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- 分期
- II/III期
- 开始
- 2024-07
- 发布
- 登记号
- NCT06413654
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 27 家列出的医院为研究中心北京、厦门、合肥、哈尔滨、天津、太原、广州、成都、昆明、杭州、武汉、沈阳、济南、温州、石家庄、福州、郑州、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
重症肌无力
Myasthenia gravis2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 3 家医院列在重症肌无力下全国有 89 家医院列在重症肌无力下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- 分期
- III期
- 开始
- 2024-06
- 发布
- 登记号
- NCT06463587
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 14 家列出的医院为研究中心上海、北京、广州、成都、武汉、沈阳、石家庄、蚌埠、遵义、郑州、长春、长沙
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文2
其他疾病
烟雾病
Moyamoya disease2021–2025 年中国大陆作者发表的 356 篇烟雾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 1.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 2 家医院列在烟雾病下全国有 47 家医院列在烟雾病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Development and Validation of Risk Prediction Models for Stroke and Cognitive Impairment in Moyamoya Disease and Moyamoya Syndrome
- 分期
- 未注明
- 开始
- 2026-08
- 发布
- 登记号
- NCT07894107
年龄 12 岁 至 70 岁(登记的条件)
牵头:首都医科大学附属北京天坛医院;另有 12 家列出的医院为研究中心上海、北京、南昌、成都、杭州、武汉、苏州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Global research trends and emerging hotspots of RNF213 in Moyamoya disease: A bibliometric analysis (2011-2024).
- Transmission electron microscopy ultrastructural characteristics of the distal middle cerebral artery in moyamoya disease.
- Vasculitic Moyamoya syndrome in a patient with paroxysmal nocturnal hemoglobinuria: A case report and literature review.
- Influence of Autologous Bone Marrow Stem Cell Therapy on the Levels of Inflammatory Factors and Conexin43 of Patients with Moyamoya Disease.
- Occlusion of the Anterior Cerebral Artery Mimicking a Cerebral Aneurysm: Clinical Presentation and Literature Review.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
冠心病
Coronary heart disease2021–2025 年中国大陆作者发表的 5,119 篇冠心病 PubMed 英文论文中,这家医院牵头了 26 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 6 家医院列在冠心病下全国有 231 家医院列在冠心病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- 分期
- 不分期
- 开始
- 2021-09
- 发布
- 登记号
- NCT04995159
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 67 家列出的医院为研究中心上海、中山、兰州、北京、南京、南宁、南昌、合肥、哈尔滨、天津、太原、广州、徐州、昆明、杭州、武汉、汕头、洛阳、济南、海口、淄博、淮安、湛江、烟台、珠海、石家庄、蚌埠、西安、贵阳、郑州、重庆、银川、长春、长沙、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文26
- Carotid intima thickness and elasticity combined with MHR predicting the severity of coronary artery stenosis in patients with premature coronary artery disease.
- Impact of Insomnia on Myocardial Infarction Risk and Coronary Plaque Vulnerability: Insights From Mendelian Randomization and OCT Imaging.
- Serum sST2, IL-33, and Hcy Expression in Older Adults Patients with Myocardial Infarction and Their Predictive Value for MACE.
- Elevated serum uric acid as an independent risk factor for multiple stent placement in non-hypertensive, non-diabetic patients with coronary artery disease: a retrospective cohort analysis.
- Unveiling the role of risk factors and predictive models in acute type-a aortic dissection surgery: OI downregulation and its association with immune disorders.
- Relationship Between Aldehyde Dehydrogenase 2 Gene Polymorphism and Vasodilative Effect of Nitroglycerin on Coronary Arteries.
- Insulin resistance and coronary inflammation in patients with coronary artery disease: a cross-sectional study.
- Diagnostic and prognostic value of serum Cys-C, retinol-binding protein, and ischemia-modified albumin in patients with coronary heart disease: A diagnostic accuracy study.
- Optical coherence tomography analysis of lesion characteristics and thrombus types in non ST-segment elevation myocardial infarction patients.
- Kinesiophobia and its associated factors in patients with coronary heart disease: a cross-sectional study based on latent feature analysis.
- Triglyceride-glucose index as a marker of adverse cardiovascular prognosis in patients with coronary heart disease and hypertension.
- Safety and efficacy of enterprise stenting for symptomatic atherosclerotic severe posterior circulation stenosis.
- Validation of a predictive model for coronary artery disease in patients with diabetes.
- Clinical characteristics and outcomes of Chinese patients with coronary heart disease and resistant hypertension.
- The "L-Sandwich" Strategy for True Coronary Bifurcation Lesions: A Randomized Clinical Trial.
- SPECT myocardial blood flow quantitation for the detection of angiographic stenoses with cardiac-dedicated CZT SPECT.
- GAS5/METTL14/ESR1 genetic variants are related to the susceptibility of coronary heart disease.
- Remote ischemic preconditioning can extend the tolerance to extended drug-coated balloon inflation time by reducing myocardial damage during percutaneous coronary intervention.
- Clinical and imaging characteristics of cardiac magnetic resonance presenting with myocardial infarction with non-obstructive coronary arteries in China.
- Histone Deacetylase 1 Depletion Alleviates Coronary Heart Disease Via the MicroRNA-182-Mediated Transforming Growth Factor β/Smad Signaling Pathway.
- Relationship between cognitive emotion regulation strategies and coronary heart disease: an empirical examination of heart rate variability and coronary stenosis.
- Prediction of all-cause mortality in coronary artery disease patients with atrial fibrillation based on machine learning models.
- Lipid profile and prognosis in patients with coronary heart disease: a meta-analysis of prospective cohort studies.
- Suppression of microRNA-323-3p restrains vascular endothelial cell apoptosis via promoting sirtuin-1 expression in coronary heart disease.
- Analysis of Characteristics of Patients with Non-ST-Segment Elevation Myocardial Infarction by Cardiac Magnetic Resonance Imaging.
- Factors affecting in-stent restenosis after angioplasty with the Enterprise stent for intracranial atherosclerotic diseases.
中文论文(未计入)3
- [The relationship between variant angina pectoris syncope and coronary artery spastic targeted location, arrhythmia and coronary artery stenostic lesion].
- [Clinical efficacy evaluation of minimally invasive cardiac surgery coronary artery bypass grafting in patients with multivessel coronary artery disease].
- [Association of RAGE gene polymorphisms with MHR ratio and heart rate variability among patients with coronary heart disease].
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System
- Effect of Antithrombotic Treatment in Patients With Both Coronary Heart Disease and Atrial Fibrillation
- Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting
- Efficacy and Safety of the YUKON Drug Eluting Stent in Diffuse Coronary Artery Disease
其他疾病
先天性心脏病
Congenital heart disease2021–2025 年中国大陆作者发表的 2,604 篇先天性心脏病 PubMed 英文论文中,这家医院牵头了 14 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 6 家医院列在先天性心脏病下全国有 207 家医院列在先天性心脏病下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 即将招募A Multicenter Study on the Normal Reference Range and Clinical Significance of the Right Atrioventricular Coupling Index Assessed by Artificial Intelligence-Based Three-Dimensional Echocardiography
- 分期
- 未注明
- 开始
- 2025-12
- 发布
- 登记号
- NCT07292896
年龄 18 岁 至 79 岁(登记的条件)
牵头:中国医科大学附属第一医院;另有 11 家列出的医院为研究中心上海、北京、太原、成都、武汉、沈阳、深圳、西安、郑州、长春、青岛
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文14
- Identification of novel biallelic mutations in CFAP53 associated with fetal situs inversus totalis and literature review.
- Remimazolam for successful sedation in children with left-to-right shunt congenital heart disease: An up-and-down sequential allocation trial.
- Unveiling the role of risk factors and predictive models in acute type-a aortic dissection surgery: OI downregulation and its association with immune disorders.
- Impacts of gene variants on drug effects-the foundation of genotype-guided pharmacologic therapy for long QT syndrome and short QT syndrome.
- Identifying the critical windows of temperature extremes exposure and congenital heart diseases.
- Alternating Early Afterdepolarizations Underlying Bradycardia-Dependent Macroscopic T Wave and Discordant Mechanical Alternans.
- Trans-jugular transcutaneous closure of atrial septal defects with an adjustable curved sheath under echocardiography guidance.
- Peratrial device closure of perimembranous ventricular septal defects via a small right subaxillary incision: Midterm results in patients <12 months of age.
- A novel mutation in PCD-associated gene DNAAF3 causes male infertility due to asthenozoospermia.
- Preoperative sedation in children with congenital heart disease: 50% and 95% effective doses, hemodynamic effects, and safety of intranasal dexmedetomidine.
- Different effects of maternal homocysteine concentration, MTHFR and MTRR genetic polymorphisms on the occurrence of fetal aneuploidy.
- Exploration and validation of hub genes and pathways in the progression of hypoplastic left heart syndrome via weighted gene co-expression network analysis.
- Knockdown of Long Noncoding RNA SNHG14 Protects H9c2 Cells Against Hypoxia-induced Injury by Modulating miR-25-3p/KLF4 Axis in Vitro.
- Asymmetric Occluder Occlusion of Outlet Ventricular Septal Defect Via a Subaxillary Approach.
中文论文(未计入)3
- [Genetic analysis of primary ciliary dyskinesia caused by DNAH5 splicing site mutations].
- [Early warning of low maternal unconjugated estriol level by prenatal screening for fetus with X-linked ichthyosis].
- [Effect and prognosis of new type of re-dilated stent in the treatment of pulmonary artery bifurcation stenosis].
其他疾病
脊柱侧弯
Scoliosis2021–2025 年没有牵头脊柱侧弯的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 2 家医院列在脊柱侧弯下全国有 107 家医院列在脊柱侧弯下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月18日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery
- 分期
- IV期
- 开始
- 2026-04
- 发布
- 登记号
- NCT07229495
年龄 10 岁 至 17 岁(登记的条件)
牵头:北京协和医院;另有 5 家列出的医院为研究中心上海、北京、南昌、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 6 家医院列在抗 NMDA 受体脑炎下全国有 124 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
大动脉炎
Takayasu arteritis2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 2 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 8 家医院列在特发性肺纤维化下全国有 288 家医院列在特发性肺纤维化下
这家医院参与的开放试验 2
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- 分期
- III期
- 开始
- 2026-09
- 发布
- 登记号
- NCT07687459
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 45 家列出的医院为研究中心上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、运城、郑州、长春、长沙
- 正在招募A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- 分期
- II期
- 开始
- 2025-11
- 发布
- 登记号
- NCT07121413
年龄 40 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、南京、南昌、呼和浩特、天津、广州、徐州、成都、杭州、郑州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文5
- Antidepressant intervention to possibly delay disease progression and frailty in elderly idiopathic pulmonary fibrosis patients: a clinical trial.
- Potential function exploration of lncRNAs in idiopathic pulmonary fibrosis: insights from whole transcriptome sequencing data analysis.
- Integrative Analysis of Endothelial Cell Senescence-Related Genes in Idiopathic Pulmonary Fibrosis.
- Genetic association of telomere length, obesity and tobacoo smoking with idiopathic pulmonary fibrosis risk.
- Contribution of Adiponectin/Carnitine Palmityl Transferase 1A-Mediated Fatty Acid Metabolism during the Development of Idiopathic Pulmonary Fibrosis.
早期论文(2016–2020 年)3
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
- Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis
- Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis
- Zephyrus I: Evaluation of Efficacy and Safety of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年中国大陆作者发表的 779 篇肌萎缩侧索硬化症 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 3 家医院列在肌萎缩侧索硬化症下全国有 182 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
其他疾病
杜氏肌营养不良
Duchenne muscular dystrophy2021–2025 年中国大陆作者发表的 213 篇杜氏肌营养不良 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.5%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 5 家医院列在杜氏肌营养不良下全国有 111 家医院列在杜氏肌营养不良下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的杜氏肌营养不良开放试验。
这些数字背后的记录
牵头的论文1
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 3 家医院列在IgA 肾病下全国有 300 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
其他疾病
成骨不全症
Osteogenesis imperfecta2021–2025 年没有牵头成骨不全症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 3 家医院列在成骨不全症下全国有 58 家医院列在成骨不全症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年没有牵头原发性胆汁性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 2 家医院列在原发性胆汁性胆管炎下全国有 153 家医院列在原发性胆汁性胆管炎下
这家医院参与的开放试验 3
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- 分期
- III期
- 开始
- 2025-12
- 发布
- 登记号
- NCT07282353
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 35 家列出的医院为研究中心上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、宝鸡、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛
- 正在招募Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- 分期
- II/III期
- 开始
- 2023-02
- 发布
- 登记号
- NCT05749822
年龄 18 岁 至 75 岁(登记的条件)
牵头:空军军医大学西京医院;另有 11 家列出的医院为研究中心北京、南京、天津、广州、延安、成都、昆明、沈阳、西安、郑州、长沙
- 正在招募Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- 分期
- III期
- 开始
- 2023-09
- 发布
- 登记号
- NCT06051617
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)4
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
其他疾病
原发性硬化性胆管炎
Primary sclerosing cholangitis2021–2025 年没有牵头原发性硬化性胆管炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
郑州有 1 家医院列在原发性硬化性胆管炎下全国有 89 家医院列在原发性硬化性胆管炎下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- 分期
- III期
- 开始
- 2026-05
- 发布
- 登记号
- NCT07387549
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
遗传性大疱性表皮松解症
Inherited epidermolysis bullosa2021–2025 年中国大陆作者发表的 56 篇遗传性大疱性表皮松解症 PubMed 英文论文中,这家医院牵头了 2 篇,占 3.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 3 家医院列在遗传性大疱性表皮松解症下全国有 41 家医院列在遗传性大疱性表皮松解症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性大疱性表皮松解症开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
遗传性血管性水肿
Hereditary angioedema2021–2025 年没有牵头遗传性血管性水肿的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 1 家医院列在遗传性血管性水肿下全国有 30 家医院列在遗传性血管性水肿下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的遗传性血管性水肿开放试验。
这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
Leber 遗传性视神经病变
Leber hereditary optic neuropathy2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 3 篇,占 5.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
郑州有 2 家医院列在Leber 遗传性视神经病变下全国有 30 家医院列在Leber 遗传性视神经病变下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。
这些数字背后的记录
牵头的论文3
- Abnormal cerebral blood flow in patients with Leber's hereditary optic neuropathy.
- Proteomic Profiling Reveals Increased Glycolysis, Decreased Oxidoreductase Activity and Fatty Acid Degradation in Skin Derived Fibroblasts from LHON Patients Bearing m.G11778A.
- Occult primary white matter impairment in Leber hereditary optic neuropathy.
其他相关研究
联系这家医院
出示给工作人员或司机的院名卡
河南省人民医院
Henan Provincial People's Hospital
郑州
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR Wikidata
People's Hospital of Zhengzhou University; Zhengzhou University People's Hospital; and Affiliated Provincial People's Hospital of Zhengzhou University; Heart Center of Henan Provincial People's Hospital; Henan Provincial People' Hospital; Affiliated People's Hospital of Zhengzhou University; Henan Provincial People's Hospital Affiliated to Zhengzhou University; and Henan Provincial People's Hospital